Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations

Uncommon epidermal growth factor receptor (EGFR) mutations account for 10%–20% of all EGFR mutations in non-small-cell lung cancer (NSCLC). The uncommon EGFR-mutated NSCLC is associated with poor clinical outcomes and generally achieved unsatisfactory effects to the current therapies using standard...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Chen, Zhang, Cong, Fu, Zhiwen, Liu, Jinmei, Zhou, Yuanfeng, Cheng, Bao, Wang, Cong, Li, Shijun, Zhang, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326255/
https://www.ncbi.nlm.nih.gov/pubmed/37425047
http://dx.doi.org/10.1016/j.apsb.2023.03.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326255/
https://www.ncbi.nlm.nih.gov/pubmed/37425047
http://dx.doi.org/10.1016/j.apsb.2023.03.007

Ejemplares similares